Erratum: Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin (Journal of Bone and Mineral Research (2010) 25, (673-675) DOI: 10.1002/jbmr.44);Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 673-675

  Frost, Morten ^a   Andersen, Tom Erenskjold ^a   Yadav, Vijay ^b   Brixen, Kim ^a   Karsenty, Gerard ^b   Kassem, Moustapha ^a,c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bone formation; High bone mass; LRP5; Serotonin; T253I

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; SEROTONIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP5 PROTEIN, HUMAN;

ARTICLE; BONE MASS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HIGH BONE MASS; HUMAN; PHENOTYPE; SEROTONIN BLOOD LEVEL; THROMBOCYTE POOR PLASMA; ADULT; BLOOD; BONE DENSITY; BONE DEVELOPMENT; FEMALE; GENETICS; MALE; METABOLISM; MUTATION;

ADULT; BONE DENSITY; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MALE; MUTATION; OSTEOGENESIS; PHENOTYPE; SEROTONIN;

EID: 77953451716     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.127     Document Type: Erratum

References (8)

1. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513-523. (Pubitemid 33152786)
2. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513-1521. (Pubitemid 34755690)
3. Van WL, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003;72:763-771. (Pubitemid 36255977)
4. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825-837.
5. Modder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res. 2010;25:415-422.
6. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188-194. (Pubitemid 46148067)
7. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82:92-101.
8. Yadav VK, Oury F, Suda N, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138:976-989.